Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Kyowa Hakko Kirin gains Japanese rights to Amgen's brodalumab

Executive Summary

Amgen Inc. licensed Kyowa Hakko Kirin Co. Ltd. exclusive development and commercialization rights in Japan and certain other Asian countries to brodalumab (AMG827) for psoriasis. KHK will rename the compound KHK4827.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register